TREATMENT OF AN INFLAMMATION OF THE TARSAL GLAND OF THE EYELID

Lien: PROJET_TARSAL_NEUROPTIS

TREATMENT OF AN INFLAMMATION OF THE TARSAL GLAND OF THE EYELID

The present invention relates to a method for treating an inflammation and/or dilatation of the

tarsal gland (or meibomian gland) of the eyelid.

Inflammation or dilatation of the tarsal gland may contribute to a number of conditions,

including blepharitis. Therefore, there is a need for therapeutic means for treating this

inflammation or dilatation.

The present invention relates to a compound selected in the group consisting of ML7 and a

functional derivative thereof, for use in a method for the treatment of an inflammation and/or

dilatation of the tarsal gland of the eyelid.

ML7, or 1-(5-iodonaphtalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine, was described in

Saitoh et al., J. Biol. Chem 1987, 262(16), p. 7796. It is derived from the ML9 molecule (1-

(5-chloro-1-sulfonyl)-1H-hexahydro-1,4-diazepine) andcapable of selectively inhibiting the

activity of the myosin light chain kinase (or MLCK).

CLAIMS

1. A compound selected in the group consisting of ML7 or a derivative thereof, for use in

a method for the treatment of an inflammation and/or dilatation of the tarsal gland of

the eyelid.

2. The compound for use according to claim 1, which is to be administered in the form of

a pharmaceutical composition further comprising a pharmaceutically acceptable

carrier.

3. The compound for use according to claim 2, wherein the pharmaceutical composition

is for topical administration to the eye.

4. The compound for use according to claim 3, wherein the pharmaceutical composition

is an eye drop composition, in particular a multi dose eye drop composition.

5. The compound for use according to claim 2 to 4, wherein the composition comprises:

- between 0,001 and 0,5 weight % of the compound;

- between 0,1 and 10 weight % of cyclodextrine; and

- between 0,01 and 0,5 weight % of hydroxypropylmethylcellulose, PVP

hydroxyethylcellulose or PVA.

6. The compound for use according to claim 5, wherein the cyclodextrine is

hydroxypropyl beta-cyclodextrine.

7. The compound for use according to any one of claim 1 to 6, wherein the compound is

ML7 or ML9.

TREATMENT OF AN INFLAMMATION OF THE TARSAL GLAND OF THE EYELID

The present invention relates to a method for treating an inflammation and/or dilatation of the

tarsal gland (or meibomian gland) of the eyelid.